Immutep (IMMP) has released an update.
Immutep has finalized discussions with the FDA for its TACTI-004 Phase III trial, aiming to treat non-small cell lung cancer with a combination of their immunotherapy efti, KEYTRUDA, and chemotherapy. This trial, which will involve around 750 patients, is significant as it includes patients with varying levels of PD-L1 expression, a marker important in cancer prognosis and treatment. Immutep’s efti has previously shown promising efficacy and safety in earlier trial phases and has received Fast Track designation by the FDA.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
